Raymond James Upgrades Lumexa Imaging Holdings, Inc. (LMRI) to Strong Buy with an Unchanged $23 Price Target

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) is among the 11 Newly-Listed NASDAQ Stocks to Buy Now.

On February 9, 2026, Raymond James upgraded Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) to Strong Buy from Outperform with an unchanged $23 price target. Raymond James cited valuation following the recent selloff, noting that Lumexa trades at a six-times EBITDA discount to RadNet (RDNT). Raymond James believes some discount is warranted but sees “several factors that should help narrow the gap over time,” including what it described as a “superior and more well-defined” external growth strategy, stronger local market fundamentals, and a growing joint venture mix.

In January 2026, multiple firms initiated coverage. Barclays began coverage on Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) with an Overweight rating and a $23 price target, highlighting strong local market positions and accelerating new center openings, as well as rising demand for diagnostic imaging tied to chronic disease trends and a shift toward lower-cost care sites. Deutsche Bank initiated Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) with a Buy rating and a $22 price target, describing Lumexa as the second-largest independent diagnostic testing facility operator in the U.S. and pointing to share gains versus hospital outpatient facilities and an expanding advanced imaging mix. Wells Fargo also initiated Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) with an Overweight rating and a $22 price target, calling the company’s growth “attractive” within an end market benefiting from lower service costs and improved patient experience.

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) operates outpatient diagnostic imaging centers in the United States, offering MRI, CT, PET, X-ray, ultrasound, and mammography services.

While we acknowledge the potential of LMRI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 12 Best Tech Stocks that Beat Earnings Estimates.

Disclosure: None. Follow Insider Monkey on Google News.